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In eukaryotes, cell cycle progression is particularly controlled at
two steps, before the transitions from G1 to S and from G2 to M
(Hall and Peters, 1996). Progression through both checkpoints is
controlled by cyclin-dependent protein kinases (CDKs) sequen-
tially regulated by cyclins D, E and A (Sherr, 1996). P15 (also
called p15INK4b, MTS2, INK4b, CDKN2B) and p16 (also known as
p16INK4a, p16INK4, MTS1, CDK4I, CDKN2A) prevent CDK activa-
tion, specifically that of CDK4 and CDK6 associated with D-type
cyclins, by blocking the binding to the cyclin regulatory subunits,
inducing G1 phase arrest (Hannon and Beach, 1994; Serrano et al,
1993). However, the activities of p15 and p16 are regulated differ-
ently. P15 is an effector of transforming growth factor-β (TGF-
β )–induced cell cycle arrest whereas p16 is not involved in
TGF–β –induced growth inhibition (Hannon and Beach, 1994). P15
is located on chromosome band 9p21 adjacent to the INK4a/ARF
locus, which encodes two unrelated proteins, p16INK4a and p14ARF,
through the use of shared coding regions and alternative reading
frames. P14ARF is a potent negative regulator of the cell cycle that
functions in a manner different from that of CDK inhibitors, via a
p53-dependent pathway (Sherr, 1998; Sharpless and DePinho,
1999). The INK4a/ARF locus is a frequent site of chromosomal
deletion in human tumours (Hannon and Beach, 1994; Jen et al,
1994). Numerous studies have identified p16 as the principal target
of these deletions (Kamb, 1995). Mutational analysis has shown
that p16 is commonly mutated or homozygously deleted in human
cancer. In particular, germline mutations specifically affecting p16
have been identified in familial melanoma (Hall and Peters, 1996;
Sherr, 1996). The methylation of the 5’-CpG island of p16 has been
proposed as another mechanism for the inactivation of this gene
(Merlo et al, 1995; Herman et al, 1995). The neighbouring p15
gene has been considered as a putative tumour suppressor gene due
to the high level of sequence identity and functional similarity
between p15 and p16. The analysis of cell lines and primary
tumours of various origins has not resulted in the identification of
any p15 gene point mutations (Stone et al, 1995; Hall and Peters,
1996; Sherr, 1996). Homozygous deletions of the p15 gene in
primary tumours and tumour cell lines almost invariably involves
the nearby p16 gene as well. Aberrant methylation of p15 is associ-
ated with the loss of transcription of this gene in leukaemias and
gliomas (Herman et al, 1996). This mechanism, which seems to
involve the p15 gene selectively, provides the sole evidence so far
of a tumour suppressor role for this gene in human neoplasia. 
Urinary bladder transitional cell carcinomas (TCCs) is the fourth
most common cancer in men and the ninth most common cancer in
women in Western countries. TCCs are either superficial [Ta-T1
tumours including TCCs confined to the urothelium (Ta) and those
invading only the lamina propria (T1)]or muscle-invasive. The
9p21 region, surrounding the INK4a/ARF locus and the p15
gene, has been found to be lost in about 50% of bladder tumours
(Reznikoff et al, 1996). Several analyses of bladder tumours
have failed to identify p15 gene point mutations (Orlow et al,
1995; Packenham et al, 1995; Miyamoto et al, 1995). Although
the homozygous deletions found in bladder tumours generally
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tion have been described (Orlow et al, 1995; Packenham et al,
1995; Williamson et al, 1995). No study has reported the inacti-
vation of p15 through a loss of expression. Basing our study on
the clear involvement of the loss of the 9p21 region in bladder
cancer, we evaluated the importance of the cell cycle inhibitor
p15 in bladder carcinogenesis, by investigating changes in p15
expression at the mRNA level in a series of 75 primary TCCs of
various stages and grades and 13 bladder cancer cell lines. As
we found a decreased expression of p15 in a significant number
of bladder tumours, we investigated several potential mecha-
nisms for this down regulation. Considering the known involve-
ment of p16 in some tumours, we have also analysed p15
expression in conjunction with p16 expression. 
MATERIALS AND METHODS 
Cell lines 
Human bladder cell lines 647V, EJ138, J82, JON53, RT112, T24,
TCCSUP were obtained and cultured as previously described (Gil
Diez de Medina et al, 1999). Lysates in 4M guanidinium thiocyanate
of the bladder cell lines HCV29, HT1376, RT4, UM-UC-3, VM-
CUB-1, VM-CUB-3, were kindly provided by Dr J Southgate
(Leeds, U.K.). 
Tissue samples 
Tumour tissues were obtained from transurethral resections or
radical cystectomy samples from 75 patients with transitional cell
carcinomas of the urinary bladder. Tumours were classified by
stage according to the TNM classification (UICC, 1992) and by
grade according to criteria recommended by the World Health
Organisation (WHO, 1973). The tumours studied were: 9 Ta
(papillary superficial non-invasive tumours), 14 T1a (lesions
invading the superficial lamina propria), 15 T1b (lesions invading
the deep lamina propria), 10 T2 (lesions invading the inner layer of
vesical muscle), 17 T3 (outer layer of the muscle invaded with or
without adipous perivesical tissue tumour invasion), and 10 T4
(tumour extension beyond the bladder). Sixteen were grade G1
(low grade), 26 grade G2 (intermediate grade), and 33 grade G3
(high grade). A representative sample was taken from each
tumour for histological assessment, and an adjacent fragment
was placed in liquid nitrogen and stored at –80˚C for subsequent
DNA and RNA extraction. Each sample included in this analysis
contained more than 80% malignant cells, as assessed by histo-
logical examination. Fourteen normal samples obtained during
organ procurement for transplantation on cadaveric donors were
also studied. They consisted of six urothelium samples obtained
by scraping off the urothelium from the submucosa of normal
bladder specimens, three lamina propria samples and five vesical
smooth muscle specimens, dissected separately. 
Primary cultures of human urothelia and 5-bromo-2´-
deoxyuridine (BrdU) incorporation 
An organo-typic culture model (de Boer et al, 1996) was used for
three normal urothelia. In order to compare p15 mRNA expression
to proliferation data in these primary cultures of human normal
urothelia, BrdU incorporation was studied at different times of the
culture (de Boer et al, 1994). Briefly, upon termination of the
culture, cells were incubated with 40 µ g/ml of BrdU in serum-free
medium for 2 h. Cultures were then rinsed with PBS, PH 7.2, and
fixed with 96% ethanol for at least 1 h for immunocytochemistry.
Before the primary anti-BrdU antibody incubation, cultures were
treated with HCl and Borax buffer. Chain-specific cytokeratin and
BrdU expressions were visualized using appropriate dilutions of
the primary mouse monoclonal antibodies in a conjugated immu-
noenzyme assay. The anti-cytokeratin and anti-BrdU antibodies
were kindly donated by Professor FCS Ramaekers (Maastricht,
Netherlands). Secondary rabbit anti-mouse (Dako, Glostrup,
Denmark) antibodies were either peroxidase-conjugated (used for
BrdU staining) or alkaline phosphatase-conjugated (used for cytok-
eratin staining). 3,3´-diaminobenzidine tetrahydrochloride (DAB)
or the diazonium salt served as chromogens, and fast red violet LB
with naphtol AS-MX phosphate served as coupling reagent (Sigma,
St Louis, USA). The number of cells immunostained with the anti-
BrdU antibody was then compared to the total cell number assessed
with the anti-cytokeratin antibody in 1 mm2 surface. 
RNA and DNA extraction 
RNA and DNA were extracted simultaneously using the
caesium chloride cushion method essentially as described else-
where (Coombs et al, 1990), but with slight modifications
(Cappellen et al, 1997; Gil Diez de Medina et al, 1997). 
RT-PCR 
p15 and p16 messenger RNA levels were determined by radioac-
tive semi-quantitative RT-PCR using TBP (TATA-binding protein)
or GAPDH as internal controls. cDNA synthesis and PCR analysis
were performed as previously described (Radvanyi et al, 1993; Gil
Diez de Medina et al, 1997). Briefly, the number of cycles was
chosen to be in the exponential part of the PCR (23 cycles for the
co-amplification of p15 and TBP, 24 for the co-amplification of
p16 and TBP and 21 for the co-amplification of TBP and
GAPDH). The primer sequences used for p15 and p16, located in
exons 1 and 2 of these genes, were: 5´-CGCTGCCCATCAT-
CATGAC-3´ (sense) and 5´-CTAGTGGAGAAGGTGCGACA-3´
(antisense) for p15 and 5´-CCAACGCACCGAATAGTTAC-3´
(sense) and 5´-CACGGGTCGGGTGAGAGT-3´ (antisense) for
p16. Primer sequences for TBP and GAPDH were as described
elsewhere (Gil Diez de Medina et al, 1997). The PCR-amplified
products were subjected to electrophoresis in 8% polyacrylamide
gels. Signals were quantified with a Molecular Dynamics 300
PhosphorImager (Molecular Dynamics, Sunnyvale, CA). There
was no amplification if reverse transcriptase was omitted from the
reverse transcription reaction. 
Homozygous deletions analysis for the p15 and p16
genes 
Homozygous deletions were detected by a PCR based assay. A
fragment located in exon 1 of p15 (or p16) was co-amplified with
a genomic fragment of either GAPDH or  PSA as a control.
GAPDH and PSA are located in chromosomal regions that are
infrequently the target of allelic loss in bladder carcinomas (less
than 3% and 7%, respectively). The primer sequences for p15,
p16, GAPDH and PSA are listed below. 
5´-GGCCAGAGCGGCTTTGAG-3´ (p15 sense) and 5´-CTGG
GCTCAGCTTCATTACC-3´ ( p15 antisense), 5´-TCGGGTA-
GAGGAGGTGCGGG-3´ (p16 sense) and 5´-GATCGGCCTCC-
GACCGTAACT-3´ ( p16 antisense), 5´-TGGGGTGGTGAATA
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GAA-3´ ( GAPDH antisense), 5´-AGGCTGGGGCAGCAT-3´
(PSA sense) and 5´-CACCTTCTGAGGGTGAACTTG-3´ ( PSA
antisense). PCR were performed with 50 ng of genomic DNA and
the number of cycles was selected so as to be in the exponential
part of the two amplification reactions (i.e. 23 cycles). PCR prod-
ucts were analysed as described in the reverse transcription-PCR
section. The relative intensity of the products obtained for the test
(p15 or p16) and control (GAPDH or PSA) sequences in normal
and tumour DNA samples was compared and the relative represen-
tation of p15 and p16 calculated as follows: 
Given the potential for tumour heterogeneity and contamination
with non-neoplastic cells, tumours with ratios below 0.3 were
considered to have homozygous deletions. 
Methylation analysis 
A quantitative PCR assay based on the inability of some restriction
enzymes to cut methylated sequences (Singer-Sam et al, 1990) was
used to analyse the methylation status of the first exon of the p15
gene. Three sets of primers flanking three different regions of exon 1
of p15 gene were designed (Figure 3). The sites examined were: one
HpaII site in fragment 1, one EagI, two HpaII and five CfoI sites in
fragment 2 and two HpaII, one SacII and ten CfoI sites in fragment
3. DNA was digested according to the manufacturer’s instructions
(New England Biolabs). DNA (1 µ g) was digested overnight at
37˚C, with 10 units of enzyme/µ g of DNA. The primer sets used for
methylation analysis of p15 exon 1 were 5´-CCTTGGCCCAGCT-
GAAAACG-3´ (sense) and 5´-ACGCAGCCGAGCTCAAAGC-3´
(antisense) for fragment 1 and, 5´-CGGCCAACGGTGGAT-
TATCC-3´ (sense) and 5´-CACACCTCGCCAACGTAGAC-3´
(antisense) for fragment 3. The primer set for fragment 2 and the
amplification reactions were as described in the homozygous dele-
tions analysis section except that 25 and 26 cycles were performed
to amplify fragments 1 and 3 of exon 1 of the p15 gene respectively,
so as to be in the linear range of the assay. The PCR-amplified
products were subjected to electrophoresis in 8% polyacrylamide
gels and an autoradiograph was produced. AflII restriction enzyme
was used as a positive control (restriction site outside the amplified
fragments) and MspI restriction enzyme as a negative control
(methylation-insensitive enzyme) for each template. 
Statistical analysis 
mRNA levels were analysed according to stage and frequencies
were analysed with the Mann-Whitney test. Correlation was esti-
mated between p15 and p16 mRNA expression. 
RESULTS 
Decreased expression of p15 mRNA in superficial TCCs 
p15 mRNA levels were determined in normal bladder tissues
(urothelium, lamina propria, muscle) and in a series of 75 TCCs
(38 superficial and 37 muscle-invasive tumours) by semi-quantita-
tive RT-PCR, using two different internal controls, TBP and
GAPDH (Figures 1, 2A and data not shown). The six normal
human urothelia studied all expressed p15 mRNA, and the levels
in the various urothelia were similar (mean value = 0.86). p15
mRNA was also detected in lamina propria (n = 3) and muscle (n =
5) (mean value 0.51 and 0.53 respectively). The superficial TCCs
(Ta, T1a, T1b) had significantly lower levels of p15 mRNA than
normal urothelium (P = 0.0015). Twenty-five of the 38 superficial
TCCs (66%) contained low levels of p15 mRNA (less than 30% of
the mean value for normal urothelium) and in 19 of these 25 TCCs,
p15 mRNA levels were close to zero. Such a decrease in p15 mRNA
levels was more frequent in the Ta-T1a tumours. In this group, 18
out of 23 tumours (78%) presented low levels of expression, versus
7 out of 15 T1b tumours (47%). In the superficial tumours that
expressed p15, p15 mRNA levels were similar to those for normal
urothelium. In contrast, in the 37 invasive TCCs (T2–T4), p15
mRNA levels varied widely from non-detectable to more than 5
times higher than the level found in normal urothelium and no
significant difference in p15 mRNA level was found between
normal urothelium and invasive TCCs (P = 0.55). We compared
Decreased expression of p15 in TCCs 1517










Figure 1 p15 mRNA levels in normal bladder (Ur, urothelium; L, lamina propria; M, smooth muscle) and primary bladder carcinomas of various stages,
determined by semi-quantitative RT-PCR, using TBP as an internal standard. RT-, PCR performed on an RNA sample from normal urothelium, incubated in
reverse transcription buffer without reverse transcriptase. Examples of p15 levels in normal tissues and in TCCs of various stages are shown 
Intensity of test sequence in tumour DNA Intensity of control in normal DNA
Intensity of control in tumour DNA Intensity of test sequence in normal DNA
 p15 mRNA levels with tumour grade and found that 12 out of 16
G1 (75%), 13 out of 26 G2 (50%) and 9 out of 33 G3 (27%) had
p15 mRNA levels less than 30% of the mean for normal urothe-
lium. Similar results were obtained if GAPDH was used as the
internal standard instead of TBP (data not shown). 
p15 mRNA expression in proliferative normal human
urothelia in an organo-typic culture model 
Cell proliferation on the cultures of normal urothelia was assessed
by BrdU incorporation. The highest level of proliferation was
obtained after 5 days’ culture (19.4% of cells immunostained with
the anti-BrdU antibody) and then it decreased slowly after 10
days’ culture. The analysis of p15 mRNA levels in this model
showed that p15 mRNA expression, present in quiescent urothelia,
did not decrease in proliferative urothelia (Table 1). 
Absence of p16 mRNA expression in normal bladder
tissues, in most superficial TCCs and in some invasive
TCCs 
p16 mRNA expression was studied in all the samples of normal
bladder tissues and in 74 (37 superficial and 37 muscle invasive
tumours) out of the 75 TCCs previously studied for p15 mRNA
expression (Figure 2B). p16 mRNA levels were non-detectable in
any of the normal bladder tissues whether they were urothelium,
lamina propria or muscle samples. In the same way, p16 mRNA
levels were non-detectable in most of the superficial TCCs; only 6
superficial tumours (1 Ta, 3 T1a and 2 T1b) out of the 37 (16%)
expressed p16. On the other hand, p16 positive tumours were more
frequent in the invasive TCCs group and concerned 13 (2 T2, 8 T3,
3 T4) of the 37 tumours (35%). No correlation was found between
p15 and p16 mRNA expression in the TCCs (correlation coeffi-
cient R2 = 0.26). p16 mRNA expression was also studied
according to tumour grade. p16 mRNA levels were non-detectable
in all the 15 G1 tumours as well as in 20 of the 26 G2 (77%) and
20 of the 33 G3 (61%) tumours. 
Homozygous deletions of p15 in bladder tumours 
The results are summarized in Table 2. Twenty-eight TCCs for
which DNA was available were tested for deletions of exon 1 of
p15 using a PCR-based assay. They comprised 12 TCCs (1 Ta, 5
T1a, 2 T1b, 1 T2, 1 T3 and 2 T4) with p15 mRNA levels less than
30% of the mean value for normal urothelium and 16 TCCs (1 Ta,
2 T1a, 2 T2, 4 T3 and 7 T4) with higher levels of p15 expression.
Homozygous deletions of the p15 gene were observed in 5 of the
12 tumours lacking p15 mRNA. No homozygous deletions were
detected in the 16 TCCs that expressed p15. The frequency of p15
homozygous deletions was 18% if the entire cohort of TCCs was
considered (5 out of 28) and 42% if the cohort was restricted to the
12 TCCs that did not express p15 (5 out of 12). Homozygous dele-
tions of p15 were found in two (1 T1a, 1 T1b) of the eight superfi-
cial TCCs and in three of the four invasive tumours. The 12 TCCs
lacking p15 expression comprised 3 G1, 6 G2 and 3 G3 tumours
and the 5 homozygous deletions of p15 involved 3 of the 6 G2 and
2 of the 3 G3 tumours. 
Homozygous deletion of p16 in bladder tumours 
To determine whether p15 deletions were selective or also involved
the p16 gene, the 5 TCCs with homozygous p15 deletions were tested
1518 MA Le Frère-Belda et al
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Figure 2 Semi-quantification data (see Materials and Methods) of p15
mRNA/TBP mRNA (A) and p16 mRNA/TBP mRNA (B) in urothelium (Ur)
and TCCs according to stage. p15 mRNA was expressed in normal
urothelium and significantly decreased in superficial tumours (mainly Ta-
T1a). In muscle invasive-TCCs (T2–T4), p15 expression differed widely
between samples. On the other hand, p16 mRNA was not expressed in
normal urothelium. In superficial TCCs, p16 mRNA was in most cases low or
non-detectable whereas in invasive TCCs, p16 mRNA levels were various.
No correlation was found between p15 mRNA and p16 mRNA levels
(correlation coefficient R2 = 0.26) 
Table 1 Quantitation of paramaters for proliferation and p15 mRNA
expression in six normal quiescent urothelia and in three primary cultures of
human urothelia. p15 mRNA expression/TBP mRNA is the mean of the ratio
of p15 mRNA to TBP mRNA in semi-quantitative RT-PCR ± the standard
deviation. The proliferation was determined as described in Materials and
Methods and is given as the mean of the percentage of BrdU positive nuclei
relative to the total number of nuclei ± the standard deviation 
Day of culture 
D0 D10 
p15 mRNA/TBP mRNA 0.9 ± 0.2 4.9 ± 2.7 
BrdU incorporation 3 ± 0.5 19.4 ± 3.4 
Table 2 Homozygous deletions of p15 in bladder tumours according to p15
mRNA expression and tumour stage. (– or + : p15 mRNA levels below or
above, respectively, 30% of the mean for normal urothelium) 
p15 mRNA expression 
– +
Tumour stage Superficial Invasive Superficial Invasive 
(n = 8) (n = 4) (n = 3) (n = 13) 
Homozygous deletion 2/8 3/4 0/3 0/13 for deletions of exon 1 of p16. All 5 tumours with homozygous p15
deletions also had homozygous deletions of p16 (data not shown). 
Lack of methylation of the CpG island in exon 1 of the
p15 gene in bladder tumours 
The 5′ region of the p15 gene contains a CpG island located around
the transcription start site. It is therefore a good candidate for hyper-
methylation-associated inactivation (Herman et al, 1996). A methy-
lation-sensitive restriction map of approximately 600-bp extending
from the promoter region through exon 1 of the p15 gene is shown
in Figure 3. A PCR-based assay was used to analyse the methylation
status of this CpG island. Double digestion with a restriction enzyme
cutting the flanking regions (AflII) and methylation-sensitive
enzymes (CfoI, HpaII, EagI, SacII) was followed by amplification
of regions 1, 2 and 3 (Figure 3). Normal urothelium showed no
methylation in any of the three regions tested (Figure 4 and data not
shown). Eight of the nine primary TCCs expressing p15 that were
tested were also unmethylated. Only one p15-expressing tumour
was methylated in region 3 of exon 1, heavily at a SacII and at a
lower level at HpaII restriction sites (Figure 4). After excluding the
possibility of homozygous deletions of p15, the methylation status
of five of the seven tumours that did not express p15 was assessed.
The five available samples showed no detectable methylation in any
of the three regions tested. Restriction of genomic DNA from one
normal urothelium and 10 tumours with the flanking enzyme
HindIII, plus the methylation-sensitive enzyme EagI, and Southern
blotting with a p15 exon 1 probe, confirmed the results obtained by
the PCR-based assay (data not shown). The p15 gene was unmethy-
lated at this EagI site in normal urothelium. All tumour tissues, both
expressing and not expressing p15, were unmethylated at this site. 
mRNA levels and homozygous deletions of p15 in
bladder tumour cell lines 
Of the 13 human bladder cell lines for which mRNA levels were
analysed, 6 cell lines had no detectable p15 mRNA and one cell
line (EJ138) had low levels of p15 mRNA (Table 3). In contrast
with the tumours, all 6 bladder cell lines with no p15 expression
presented homozygous deletions of p15, always deleted with p16
(data not shown). As expected, in the seven remaining tumour cell
lines, which expressed p15, no homozygous deletions were
detected. In the EJ138 cell line, which had very weak p15 expres-
sion, the methylation status of p15 exon 1 was studied by PCR and
Southern blotting, and no abnormal DNA methylation was
detected (data not shown). 
DISCUSSION 
A critical area of chromosomal deletion at region 9p21–22 has
been implicated in the genesis of various types of primary
tumours, including bladder carcinomas. Three negative cell cycle
regulators, p15, p16 and p14ARF, encoded by two genes located in
tandem in this region, have been identified as potential tumour
suppressors. The role of p15 in carcinomas is unclear. Indeed, no
intragenic mutation in p15 has been reported and homozygous
Decreased expression of p15 in TCCs 1519
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Figure 3 Schematic map of exon 1 of the p15 gene. Exon 1 is depicted with the non-coding region shaded grey. The positions of multiple methylation-
sensitive restriction enzyme sites and HindIII sites are shown in the sequence including exon 1 (sequence from Jen et al, 1994 and AC000049). Regions 1, 2
and 3 of p15, analysed for their methylation status using a PCR-based assay, are shown at the top. The probe used for methylation analysis by Southern
blotting (Herman et al, 1996) is shown at the bottom, along with the predicted sizes of restriction fragments 
Table 3 Homozygous deletions of p15 in bladder tumour cell lines
according to p15 mRNA levels. p15 mRNA levels are the ratio of p15 mRNA
to TBP mRNA in semi-quantitative RT-PCR. The presence (+) or absence (–)
of a homozygous deletion of the p15 gene was determined as described in
Materials and Methods 
Cell line p15 mRNA levels Homozygous deletions of p15
HCV29 0 + 
RT112 0 + 
RT4 0 + 
UM-UC-3 0 + 
VM-CUB-1 0 + 
VM-CUB-3 0 + 
EJ138 0.1 – 
J82 0.4 – 
TCCSUP 0.6 – 
HT1376 0.7 – 
T24 0.9 – 
647V 2.8 – 
JON53 3.9 – deletions of p15 almost always include the neighbouring
INK4a/ARF locus. We investigated the possible involvement of
p15 in bladder carcinomas, by comparing p15 mRNA levels in
normal urothelium and a series of derived carcinomas. 
We found that p15 was expressed in the normal urothelium 
and that p15 mRNA levels were significantly decreased in most
superficial TCCs (66%). This decreased expression was not due to
contamination of the tumour samples by normal tissue and that for
several reasons: all the TCC samples used in this analysis were
primarily composed of tumour cells, as assessed by histological
examination; contamination of the tumour by the underlying
compartments, the lamina propria and the smooth muscle, which
express p15 at a level similar to that in urothelium, would have
masked a decrease in p15 mRNA level. Furthermore, the analysis
of  p15 mRNA expression according to proliferation in normal
urothelia showed that p15 mRNA levels did not decrease in prolif-
erative urothelia thus demonstrating that lower p15 mRNA levels
encountered in Ta-T1 tumours were in fact a tumour specific alter-
ation and did not reflect a proliferative state. 
Considering the known involvement of p16 in the genesis of
various tumours and because p16 was located nearby p15, we
have also investigated p16 mRNA expression in those tumours.
We found that p16 mRNA levels were non-detectable in any of
the normal bladder samples and increased with stage and grade
of the TCCs. The absence of p16 expression in normal bladder
urothelium was in agreement with several other studies that did
not find any p16 expression in normal urothelium cultured or
uncultured neither by RT-PCR nor Western blotting nor immuno-
histochemistry (Yeager et al, 1995; Stadler et al, 1996; Benedict 
et al, 1999). In TCCs, we have found that p16 mRNA expression
was not correlated to p15 mRNA levels (correlation coefficient 
R2 = 0.26) thus indicating that the expression of the two neigh-
bouring p15 and p16 genes encoding related CDK inhibitors was
differently regulated in normal and tumour tissues. 
We investigated several possible explanations for p15 mRNA
down-regulation. Although loss of heterozygosity on chromosome
band 9p21 is a common event, p15 mRNA down-regulation in this
case cannot be due to the loss of one copy of the p15 gene, as in 26
of the 34 TCCs with decreased p15 mRNA levels there was almost
no p15 mRNA. As the p15 and p16 loci are targets for homozy-
gous deletions in bladder carcinomas, the loss of two copies of the
p15 gene may account for the down-regulation of p15 reported
herein. To avoid underestimation of homozygous deletions due to
the presence of even small amounts of contaminating normal
tissue, a semi-quantiative PCR assay was performed with a limited
number of PCR cycles (see Materials and Methods). The
frequency of homozygous deletions at the p15 locus in primary
TCCs in this study (18%) was similar to that in several other
studies (Spruck et al, 1994; Orlow et al, 1995; Packenham et al,
1995; Williamson et al, 1995). The p15 homozygous deletions that
we observed were always associated with p16 deletions and were
present in less than half the primary bladder tumours with little or
no  p15 expression. In primary tumours, homozygous deletions
were not the sole mechanism of p15 down-regulation. In contrast,
the frequency of homozygous p15 deletions was much higher in
the bladder cell lines tested (about 50%) than in primary tumours.
These deletions, in all but one case, account for the lack of expres-
sion in cell lines. Differences in the frequency of homozygous
deletions in primary tumours and cell lines for certain tumour
types including bladder carcinomas have been reported indepen-
dently by many studies (Spruck et al, 1994; Southgate et al, 1995;
Williamson et al, 1995). Homozygous deletions in cell lines may
confer a long-term growth advantage in vitro (Spruck et al, 1994).
Transcriptional repression by DNA methylation of the CpG island
in the 5’ region of p15 may be an additional mechanism of inacti-
vation of this gene in primary bladder carcinomas. This mecha-
nism, specifically involving the p15 gene, has already been
reported by Herman et al (1996) in leukaemias and some gliomas.
In bladder tumours, and similarly to Gonzalez-Zulueta et al
(1995), we observed no hypermethylation-associated inactivation
of p15 suggesting that this epigenetic mechanism is not involved
in bladder carcinomas. 
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Figure 4 Methylation status of the first exon of the p15 gene. A representative methylation-sensitive PCR analysis (region 3 of exon 1) of normal urothelium and
neoplastic cells from 3 TCCs is shown. p15 + and p15 are samples with or without p15 expression respectively. The lanes are: PCR products obtained from DNA
samples digested with AflII (A : cutting outside the region analysed) as positive control; AflII plus MspI (A+M : cutting within the region analysed and methylation-
insensitive) as negative control; AflII plus CfoI (A+C) or SacII (A+S) or HpaII (A+H) (all 3 cutting within the region analysed and methylation-sensitive) The decreased p15 expression in tumours without homozygous
deletions, may be due to a pathway involved in p15 regulation. As
the p15 protein is a major mediator of the antiproliferative effects
of TGF-β (Hannon and Beach, 1994), an abnormality in the TGF-
β signalling pathway associated with the resistance of cancer cells
to TGF-β -induced growth inhibition (Markowitz et al, 1996) could
result in p15 mRNA down-regulation. 
It is interesting to note that p15 mRNA levels were significantly
decreased in most superficial TCCs, whereas 76% of invasive
TCCs had p15 mRNA levels similar to or higher than those found
in normal urothelium. P15 and p16 are cell cycle regulatory
proteins that prevent CDK4 activation. The cyclinD-CDK4
complex catalyses the phosphorylation of pRb, which releases
E2F, resulting in G1 to S cell cycle progression. It has been
reported that tumour cells with mutations in Rb express very high
levels of wild-type p16 whereas pRb-positive tumour cells
frequently show little or no p16 (Yeager et al, 1995; Hall and
Peters, 1996). Similarly, we can suppose that a target molecule
downstream from p15 may be inactivated in some invasive
tumours, thereby inducing p15 up-regulation. 
In conclusion, our results suggest that p15 mRNA down-regula-
tion is a frequent event in early neoplastic transformation of the
urothelium and provide the first evidence for the possible involve-
ment of this gene in carcinomas. 
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